The global artificial organs market size 2026 was valued at USD 18.91 million in 2025 and is projected to grow from USD 27.86 million in 2026 to USD 177.06 million by 2034, at a remarkable CAGR of 26.01% during the forecast period (2026–2034).
Artificial organs are engineered devices implanted or integrated into the human body to replace the function of a natural organ. Rapid advances in biomedical engineering, growing chronic disease burden, and widening gaps between organ availability and patient demand are collectively fueling this market's expansion.
Key Market Drivers
1. Rising Organ Failure Incidences Organ failure has become a global health crisis. In the U.S. alone, approximately 37 million people live with kidney disease, and around 808,000 suffer from kidney failure. As of September 2023, nearly 108,000 patients were on the organ transplant waiting list (HRSA, 2024), while only about 14,000 organs were received from deceased donors in 2021 — a stark imbalance driving demand for artificial alternatives.
2. Growing Aging Population & Chronic Diseases Rising incidence of cardiovascular disease, diabetes, and chronic kidney disease among aging populations globally is increasing cases of organ failure. Approximately 620 million people worldwide live with heart and circulatory diseases, with 60 million new cases annually.
3. Robust R&D Investment Governments and private players are aggressively funding research. In 2023, CARMAT received USD 9.4 million from the European Innovation Council. BiVACOR Inc. raised USD 13 million in February 2024 to support clinical trials for total artificial heart implants. AWAK Technologies secured USD 20 million in 2023 to advance its wearable dialysis device.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/artificial-organs-market-101839
Key Market Restraints
High Procedural Costs The steep cost of artificial organ procedures remains a major barrier. An artificial heart — including surgery, device, and ongoing medical surveillance — can cost between USD 100,000 and USD 300,000 per patient in the first year. The European Commission-approved CARMAT artificial heart carries a price tag of approximately USD 180,000, limiting affordability and widespread adoption.
Market Segmentation
By Organ Type
- Artificial Heart dominates with a 91.60% market share in 2026, largely because only two FDA/CE-approved total artificial heart devices exist globally.
- Artificial Kidney is the fastest-growing segment, driven by innovations like wearable kidney devices and advancing clinical trials.
- Artificial Lung & Others remain in early developmental stages.
By Fixation
- Implantable devices hold a dominant 90.14% share in 2026, valued for long-term durability and reduced need for repeated surgical intervention.
- Wearable devices are still in early development stages but offer promising patient convenience.
By Material
- Polyurethane leads with 91.99% market share in 2026, thanks to its superior biocompatibility, flexibility, and durability.
- Silicon-based devices face limitations in mechanical strength.
By End-User
- Academic & Research Institutes lead due to increasing government funding and active R&D programs.
- Hospitals are witnessing growth through industry collaborations bringing new clinical solutions to practice.
Regional Insights
Region
2025 Market Value
Market Share
North America
USD 10.52 million
55.61%
Europe
USD 8.39 million
44.39%
Asia Pacific
Growing steadily
—
Latin America & MEA
Nascent stage
—
- North America leads the global market, backed by FDA-approved devices from SynCardia Systems, significant R&D investment, and government programs like Advancing American Kidney Health.
- Europe is second, powered by CARMAT's CE-marked artificial heart and strong public-private R&D collaboration.
- Asia Pacific is poised for steady growth, supported by aging demographics, high chronic disease burden, and government-backed innovation programs in Japan, China, and India.
Competitive Landscape
The market is highly consolidated, with very few players currently offering approved products:
- CARMAT (France) — CE-approved total artificial heart
- SynCardia Systems, LLC (U.S.) — Only FDA-approved total artificial heart; received updated FDA authorization for portable driver software in February 2023
- BiVACOR Inc. (Australia) — Emerging player in total artificial heart clinical trials
- AWAK Technologies (Singapore) — Wearable dialysis device
- Wearable Artificial Organs, Inc. (U.S.) — Pipeline stage
Conclusion
The artificial organs market is one of the fastest-growing segments in medical devices, underpinned by an urgent and growing global need for organ replacement solutions. With only a handful of approved products currently available, the market is ripe for disruption as clinical trials advance and regulatory approvals materialize. Stakeholders who invest early in R&D, partnerships, and regulatory strategy are well-positioned to capitalize on this high-growth opportunity through 2034.